Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020

Rhea-AI Summary

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit on September 23, 2020, at 8 a.m. EDT. Dinesh V. Patel, Ph.D., the company's President and CEO, will engage in a fireside chat during the event. A live and archived webcast will be available via this link and on the Protagonist website. Protagonist focuses on novel peptide-based therapeutics for unmet medical needs, with three clinical-stage assets including PTG-300 and PTG-200.

NEWARK, Calif., Sept. 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Virtual Summit 2020.

Presentation details:
Date: Wednesday, September 23, 2020
Time: 8 a.m. EDT

A live and archived webcast will be available at https://wsw.com/webcast/jeff143/ptgx/1876505 and in the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-jefferies-next-generation-ibd-therapeutics-virtual-summit-2020-301133581.html

SOURCE Protagonist Therapeutics, Inc.

FAQ

What is Protagonist Therapeutics participating in on September 23, 2020?

Protagonist Therapeutics will participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit.

Who from Protagonist Therapeutics will speak at the Jefferies Summit?

Dinesh V. Patel, Ph.D., President and CEO of Protagonist Therapeutics, will participate in a fireside chat.

What time will the Protagonist Therapeutics presentation take place?

The presentation is scheduled for 8 a.m. EDT on September 23, 2020.

Where can I watch the Protagonist Therapeutics webcast?

The webcast can be watched live and archived at https://wsw.com/webcast/jeff143/ptgx/1876505 and on the Protagonist website.

What are the clinical-stage assets of Protagonist Therapeutics?

Protagonist has three clinical-stage assets: PTG-300, PTG-200, and PN-943, targeting various medical conditions.